Key result
Chemotherapy for stage III-IV endometrial cancer is linked to a ~27% incidence of VTE.
Why the study?
Patients with advanced endometrial cancer are at risk for venous thromboembolism, but risk by treatment phase remains unclear.
What is the incidence and timing of venous thromboembolism in patients with advanced endometrial cancer receiving chemotherapy?
Cohort (n=84)
No
What is the incidence and timing of venous thromboembolism in patients with advanced endometrial cancer receiving chemotherapy?
Patients with advanced endometrial cancer have a high incidence of VTE (27.4%) during chemotherapy, and the Khorana score is inadequate for risk stratification in this population.
Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III-IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8-38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.
No takes yet. Share an insight, caveat, or question.
Llanora et al. (2025) conducted a cohort in Advanced endometrial cancer (n=84). Neoadjuvant chemotherapy vs. Adjuvant chemotherapy was evaluated on Overall VTE incidence (95% CI 18.8-38.0). In patients with stage III-IV endometrial cancer receiving chemotherapy, the overall incidence of venous thromboembolism was 27.4% (95% CI, 18.8-38.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: